Related Experiment Videos
Advances in pharmacotherapy for obesity
M Carruba1, C Tomello, L Briscini
1Centre for the Study and Research on Obesity, LITA Vialba, School of Medicine, Ospedale L. Sacco, University of Milan, Italy.
Summary
Metabolic enhancers, like beta3-adrenoceptor agonists, aid weight loss by increasing energy expenditure. A new selective antagonist, SR59230A, helps study these compounds in various systems.
Area of Science:
- Pharmacology
- Obesity Research
- Metabolic Regulation
Background:
- Anorectic drugs are used for weight management, but metabolic enhancers that increase energy expenditure are crucial.
- Beta3-adrenoceptor agonists are thermogenic agents, but early versions showed limited efficacy and side effects in humans.
- A Chinese hamster ovary (CHO) cell system using the human beta3-adrenoceptor gene identified potential new agonists.
Purpose of the Study:
- To investigate the development of metabolic enhancers for obesity treatment.
- To evaluate the utility of a selective beta3-antagonist (SR59230A) in studying beta3-agonist activity.
Main Methods:
- Utilized a CHO transfection system with the human beta3-adrenoceptor gene.
- Characterized the selective beta3-antagonist SR59230A.
- Examined beta3-agonist activity in rat and human model systems using SR59230A.
Main Results:
- SR59230A effectively blocked agonist activity against rat adrenoceptors and human beta3-receptor isoforms in the CHO system.
- SR59230A demonstrated competitive inhibition of agonist activity in both rat and human models.
- In vitro activity of beta3-agonists may not always predict in vivo effects due to cellular complexity.
Conclusions:
- SR59230A serves as a valuable pharmacological tool for studying newly identified beta3-receptor agonists.
- Further research is needed to bridge the gap between in vitro and in vivo efficacy of beta3-agonists.
- Targeting beta3-adrenoceptors remains a promising strategy for obesity treatment through metabolic enhancement.